ClinicalTrials.gg

Dermatitis, Atopic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,594 studies for Dermatitis, Atopic across more than 10 countries. 287 are recruiting or about to start. 1,424 of them are mainly about Dermatitis, Atopic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,638 studies for Dermatitis, Atopic. How that becomes 1,590 here

This page counts the studies the registry files under Dermatitis, Atopic, and those it files under no condition that list Dermatitis, Atopicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,638Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −12List Dermatitis, Atopic as a condition, but the registry did not file them under itMost often written as “Atopic Dermatitis Eczema” (4), “Eczema Atopic Dermatitis” (4), and “Pruritus in Patients With Atopic Dermatitis” (1). The registry filed them under other conditions only, most often Eczema (5) and Psoriasis (4).
  3. −36Match it another way23 name it in the title and 13 by a synonym or other text the search reads.
  4. 1,590The count on this page70 of them list Dermatitis, Atopic in their own words; the registry filed them under no condition.

Status

Completed
973
Recruiting
194
Terminated
114
Status unknown
92
Active, not recruiting
79
Not yet recruiting
76

Phase

Phase 2
430
Phase 3
252
Phase 1
240
Phase 4
136
Early Phase 1
12

Where

United States
639
Germany
230
Canada
225
China
206
Poland
159
France
126

Who develops what

Add Dermatitis, Atopic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 110 programs from 74 companies, 107 with this as their studies’ main aim; 29 with a live phase 3 study; 44 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, AbbVie and Innovent Biologics here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
dupilumabRecent, repeated
Evidence
  • NCT07783425 · Pfizer · Phase 3 · live · comparator · “Dupilumab” · registered Aug 2026
  • NCT07754786 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Dupilumab Injection” · registered Aug 2026
  • NCT07386743 · Jiangsu Genscend Biopharmaceutical Co., Ltd · Phase 3 · live · comparator · “DUPIXENT®” · registered Jan 2026
  • NCT07399067 · Innovent Biologics, Inc. · Phase 2 · live · comparator · “Dupilumab” · registered Jan 2026
  • NCT07330934 · Innovent Biologics, Inc. · Phase 2 · comparator · “Dupilumab” · registered Dec 2025
Sanofi56% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2017)EU: Sanofi (EMA 2017)711 studies
Topical CorticosteroidRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06554847 · 3SBio Inc. · Phase 3 · background · “Topical corticosteroid” · registered Aug 2024
  • NCT06241118 · Sanofi · Phase 3 · live · background · “Topical corticosteroids” · registered Jan 2024
  • NCT06224348 · Sanofi · Phase 3 · background · “Topical corticosteroids” · registered Jan 2024
  • NCT05559359 · Eli Lilly and Company · Phase 3 · live · background · “Topical Corticosteroid (TCS)” · registered Sep 2022
  • NCT05492578 · Sanofi · Phase 3 · live · background · “Topical corticosteroids” · registered Aug 2022
AbbVie67% of its industry studies35 studies

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
upadacitinibApproved: US 2019 · EU 2019☆ Track4 live phase-3 studies: NCT06389136, NCT06461897, NCT06701331AbbVie
ICP-332☆ Track1 live phase-3 study: NCT06775860InnoCare Pharma Limited
difamilastApproved: US 2026☆ Track2 live phase-3 studies: NCT07184645, NCT07173478Otsuka Holdings Co., Ltd.
comekibart☆ Track1 live phase-3 study: NCT07540442Shanghai Mabgeek Biotech.Co.Ltd
stapokibart☆ Track3 live phase-3 studies: NCT06495229, NCT07106372, NCT06956196Keymed Biosciences Co.Ltd

The 5 in phase 3 with the nearest primary completion, of 110 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (44)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.upadacitinib · AbbVie · Phase 3 main aim+ Upadacitinib 30mg Dose vs dupilumabNCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — primary endpoint: Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) · 184 enrolled
  • Nov 2026 est.zumilokibart · AbbVie · Phase 2 main aimNCT06395948 A Study Evaluating APG777 in Atopic Dermatitis — primary endpoint: Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI) · 470 enrolled
  • 19 Nov 2026 est.JNJ-95597528 · Johnson & Johnson · Phase 2 main aimNCT07230860 A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis — primary endpoint: Proportion of Participants with Eczema Area and Severity Index (EASI) 75 Response at Week 12 · 189 enrolled

41 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Dermatitis, Atopic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 12 open · JAK inhibitors 11 open · Calcineurin inhibitors 4 open · Corticosteroids 1 open · Antimetabolites 1 open

Coming up

131studies finish main data collection within a year24 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger. 94 (48%) take children under 18. 4 (2%) are for women only and 0 (0%) for men only; 51 (26%) take healthy volunteers.

Recruiting studies that take each age, of 194
AgeWomenMen
1054 (28%)52 (27%)
18161 (83%)157 (81%)
30160 (82%)156 (80%)
40160 (82%)156 (80%)
50161 (83%)157 (81%)
65154 (79%)151 (78%)
75125 (64%)122 (63%)
8595 (49%)92 (47%)

Across all 1,594 studies, recruiting or not: 59% stop at 75 or younger and 45% at 65; 45% take children; 1% are for women only and 1% for men only; 23% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dermatitis, Atopic studies take

Of 224 phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo5–20 · 131 studies12 mo5–20 · 114 studies—
Phase 1/222 mo8–38 · 29 studies22 mo8–38 · 25 studies—
Phase 214 mo10–19 · 224 studies13 mo9–17 · 196 studies—
Phase 318 mo13–28 · 157 studies18 mo13–28 · 150 studies—
Phase 425 mo14–41 · 45 studies——
Interventional, no phase15 mo7–34 · 183 studies8 mo3–24 · 69 studies20 mo10–43 · 114 studies
Observational35 mo17–… · 171 studies32 mo11–84 · 74 studies61 mo19–… · 97 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered17

Show 12 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,594. Browse all 1,594 → or search them.